This research established an association between Val158Met COMT (G1947A) polymorphism and preeclampsia, cytokines gene expression, and COMT genotypes.

For data collection in total, 100 women were enrolled, half belonged to the clinical population, and the other half was the control group to compare the obtained findings. 50 preeclampsia and 50 healthy pregnant women were enrolled. The PCR/RFLP did COMT genotyping, TNF-α, IL-1β, and IL-6 mRNA levels were determined by real-time PCR.

The obtained findings after the comparison and analysis were that the variant (AA) homozygotes carried 3.7-fold increased preeclampsia odds, especially for severe (OR = 9.0, 95%CI (2.09–38.799)) and early forms (OR = 6.6, 95%CI (1.62–26.87)). AA homozygotes with PE had higher TNF-α levels than controls (P = 0.012); therefore, it can be a significant identifier.

The study concluded through its findings that the Val158Met COMT polymorphism increases preeclampsia risk. TNF-α expression and Val158Met COMT polymorphism have concomitant roles in PE pathogenesis. Further studies are required on the subject matter.